B-cell Lymphoma Refractory
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| golcadomide | GH Research PLC (GHRS) |
Frequently asked questions
How many drugs are in development for B-cell Lymphoma Refractory?
BioSniper tracks 1 drug in development for B-cell Lymphoma Refractory across 1 company.
How many clinical trials target B-cell Lymphoma Refractory?
There are 4 clinical trials targeting B-cell Lymphoma Refractory tracked by BioSniper.
What is the prevalence of B-cell Lymphoma Refractory?
The estimated prevalence of B-cell Lymphoma Refractory is approximately 56.0 per 100,000 population.
Deep-dive into B-cell Lymphoma Refractory
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis